



Amvi
Biotech Incorporation.

AMERICAN VIETNAMESE BIOTECH INC

Head Office: 4th Floor, Phu Ma Duong Building, No. 85 Hoang Van Thai Street, Tan My Ward, Ho Chi Minh City, Vietnam.

Tel: 0243 215 1114 - Website: <https://www.amvibiotech.com/>

**NOTICE OF INVITATION
TO THE 2026 ANNUAL GENERAL MEETING OF SHAREHOLDERS
OF AMERICAN VIETNAMESE BIOTECH INC**

To: Shareholder of American Vietnamese Biotech Inc

The Board of Directors ("BOD") of American Vietnamese Biotech Inc. (the "Company" or "AMV") respectfully invites shareholders to attend the 2026 Annual General Meeting of Shareholders ("AGM") with the following details:

- 1. Time:** 09:00 AM, Tuesday, 30 June 2026.
- 2. Address:** Marron A&B Meeting Room, 2nd Floor, Hotel du Parc Hanoi, No. 84 Tran Nhan Tong Street, Hai Ba Trung Ward, Hanoi City, Vietnam.
- 3. Main Agenda of the Meeting:** To approve (3.1) Report on the operating results of the Board of Directors in 2025 and its operational orientation for 2026; (3.2) Report on the activities of the Independent Member of the Board of Directors and the results of the assessment of the Board of Directors' performance in 2025; (3.3) Report on the activities of the Supervisory Board in 2025 and its operational plan for 2026; (3.4) Proposals regarding the approval of the profit distribution plan, remuneration of the Board of Directors and the Supervisory Board, selection of the independent auditing firm for 2026, and other matters falling within the authority of the General Meeting of Shareholders.
- 4. Meeting Agenda and AGM Documents:** Shareholders may access the AGM documents on the Company's website at: <https://amvibiotech.com/danh-muc/ban-tin-co-dong/> from 08/06/2026.
- 5. Eligibility to Attend:**

Shareholders recorded in the shareholder list as of the record date of 01 June 2026 shall be entitled to attend the AGM. Shareholders who are unable to attend may authorize another person to attend on their behalf by using the Company's proxy form enclosed herewith or another authorization document prepared in accordance with applicable civil laws.

6. Registration and Attendance Confirmation:

- To facilitate the organization and reception of shareholders, shareholders are kindly requested to confirm their attendance or submit a proxy authorization **before 5:00 p.m. on 29 June 2026** through one of the following methods: direct submission, postal/courier service, fax or email to:
 - + *American Vietnamese Biotech Inc.*
 - + *Address: 4th Floor, Phu Ma Duong Building, No. 85 Hoang Van Thai Street, Tan My Ward, Ho Chi Minh City, Vietnam.*
 - + *Email: chungkhoanamv@gmail.com*
 - + *Tell: 0243 215 1114*
- Upon arrival at the AGM venue, shareholders or their authorized representatives are requested to present the following documents for registration procedures: Original valid identification documents (Identity Card/Citizen Identity Card/Passport or other legally accepted identification documents); Proxy Letter (for authorized representatives); AGM Invitation Letter issued by the Company.
- Detailed procedures for participation in the AGM are set out in the Regulation on Organization of the 2026 Annual General Meeting of Shareholders, which has been published on the Company's website.

Respectfully!

ON BEHALF OF THE BOARD OF DIRECTORS



NAKATANI YOSHITAKA



Amvi



....., 2026

**PROXY AUTHORIZATION LETTER
FOR ATTENDANCE AT THE 2026 ANNUAL GENERAL MEETING OF SHAREHOLDERS
AMERICAN VIETNAMESE BIOTECH INC (AMV)**

To: THE BOARD OF DIRECTORS OF AMERICAN VIETNAMESE BIOTECH INC

Name of Authorizing Shareholder:

ID Card/Citizen Identification Card/Passport/Shareholder Registration Certificate/Enterprise Registration Certificate
No:

Date of Issue: Place of Issue:

Address:

Full name of the Legal Representative/Authorized Representative (for institutional shareholders):
.....

Being a shareholder currently owning: shares of American Vietnamese Biotech Inc
according to the shareholder list finalized 01/06/2026.

Pursuant to the Invitation Notice for the 2026 Annual General Meeting of Shareholders of AMV, I hereby confirm
my attendance arrangement as follows (*please mark (X) or (✓) in the appropriate box*):

☐ Authorize Ms. Dang Nhi Nuong – Member of the Board of Directors and Director;

☐ Authorize the following individual/organization:

Name of Authorized Individual/Organization:

ID Card/Citizen Identification Card/Passport/Shareholder Registration Certificate/Enterprise Registration Certificate
No.:

Date of Issue: Place of Issue:

Number of Shares Authorized: shares.

The above-mentioned proxy is authorized to represent me in attending the **2026 Annual General Meeting of Shareholders of AMV** and to exercise all rights and perform all obligations at the Meeting corresponding to the number of shares authorized, in accordance with applicable laws and the Charter of AMV.

This Proxy Authorization Letter shall be effective from the date of signing and shall automatically terminate upon completion of the authorized matters.

I hereby undertake to accept and shall not raise any claim or complaint regarding any voting results or decisions made by my authorized representative stated above.

AUTHORIZED REPRESENTATIVE / ATTENDEE

(Signature and Full Name)

AUTHORIZING SHAREHOLDER

(Signature and Full Name)

Notes: Shareholders shall fully provide the full name, ID Card/Citizen Identification Card/Passport/Shareholder Registration Certificate/Enterprise Registration Certificate number, place of issue and date of issue of the authorized person. In case a shareholder authorizes the Member of the Board of Directors or another person, please mark (X) or (✓) in the corresponding box.

Please send this Proxy Authorization Letter to: Level 4, Phu Ma Duong Building, No.85 Hoang Van Thai, Tan Phu Ward, Hochiminh City, Vietnam, or via email at: chungkhoanamv@gmail.com no later than 5:00 PM on 29 June 2026.

In the case where the authorizing shareholder is an organization, the legal representative or the lawfully authorized representative of such organization shall sign and affix the seal thereto.

Please bring this Proxy Authorization Letter when attending the 2026 Annual General Meeting of Shareholders of American Vietnamese Biotech Inc.



AMERICAN VIETNAMESE BIOTECH INC

Head office: 4th Floor, Phu Ma Duong Building, No. 85 Hoang Van Thai Street, Tan My Ward, Ho Chi Minh City, Vietnam .

Tel: 0243 215 1114 - Website: <https://www.amvibiotech.com/>

AGENDA OF THE 2026 ANNUAL GENERAL MEETING OF SHAREHOLDERS

Time: 09:00 AM, Tuesday, June 30, 2026.

Address: Marron A&B Room, 2nd Floor, Hotel du Parc Hanoi, 84 Tran Nhan Tong Street, Hai Ba Trung District, Hanoi City, Vietnam .

TIME	CONTENT
08:30 – 09:00	<ul style="list-style-type: none"> - Welcome guests and delegates. - Verify shareholder eligibility, register attending shareholders, and distribute meeting materials.
09:00 – 09:15	<ul style="list-style-type: none"> - Report on the results of shareholder eligibility verification. - Declare the opening reason of the General Meeting and introduce attending delegates.
09:15 – 09:30	<ul style="list-style-type: none"> - Approve the Presidium, the Secretariat, and the Vote Counting Committee. - Approve the Meeting Agenda and the Regulations on the Organization of the Meeting.
09:30– 10:30	<p>The General Meeting listens to the Board of Directors (“BOD”), the Board of Management (“BOM”), and the Board of Supervisors (“BOS”) presenting the Reports and Proposals:</p> <ul style="list-style-type: none"> - Report on the BOD's performance in 2025 and operational orientations for 2026; - Report on the performance of the Independent Members of the BOD and the evaluation results of the BOD's operations in 2025; - Report on the 2025 business performance by the Board of Management and the 2026 business plan; - Report on the BOS's operations in 2025 and operational plan for 2026; - Proposal of the BOD on the approval of the Audited 2025 Financial Statements; - Proposal of the BOD on the approval of the 2025 profit distribution plan; - Proposal of the BOD on the remuneration plan for the BOD and the BOS in 2025 and the remuneration budget for 2026; - Proposal of the BOS on the selection of an auditing firm for the 2026 Financial Statements; - Proposal of the BOD on the update of the Company's business lines and sectors; - Other matters within the authority of the Meeting (if any).
10:30 – 10:45	Discussion and voting to approve the contents presented at the General Meeting
10:45 – 11:00	Break
11:00 – 11:10	Approve the Meeting Minutes and the Resolution of the General Meeting
11:10 – 11:20	Closing of the General Meeting



Amvi
Biotech Incorporation.

THE 2026 ANNUAL GENERAL MEETING OF SHAREHOLDERS

AMERICAN VIETNAMESE BIOTECH INC



Date: .../.../2026



VOTING CARD

NAME OF SHAREHOLDER/
AUTHORIZED REPRESENTATIVE

SHAREHOLDER CODE:

.....

TRADING REGISTRATION NO.:

.....

NUMBER OF VOTING SHARES:

..... shares

AGM documents

QR

code

This Voting Card is only valid during the 2026 Annual General Meeting of Shareholders

**THE 2026 ANNUAL GENERAL MEETING OF SHAREHOLDERS
AMERICAN VIETNAMESE BIOTECH INC**



VOTING BALLOT

DELEGATE CODE

NUMBER OF VOTING SHARES

Shareholder/Authorized Representative:

Ownership Registration No.:

Number of owned shares: shares

Number of authorized/represented shares: shares

Total number of voting shares: shares

After carefully studying the contents of the Reports and Proposals presented at the 2026 Annual General Meeting of Shareholders of American Vietnamese Biotech Inc ("AMV"), I hereby cast my vote on each specific matter as follows:

Voting Matters (Mark ✓ or X in the corresponding box)	Approve	Disapprove	No Opinion
Matter 01: To approve the Report on the BOD's performance in 2025 and operational orientations for 2026 <i>(Attached with Report No. 01/2026/AMV/BC-HĐQT)</i>			
Matter 02: To approve the Report on the performance of the Independent Members of the BOD and the evaluation results of the BOD's operations in 2025 <i>(Attached with Report No. 02/2026/AMV/BC-HĐQT)</i>			
Matter 03: To approve the Report on the 2025 business performance by the Board of Management and the 2026 business plan <i>(Attached with Report No. 03/2026/AMV/BC-BGD)</i>			
Matter 04: To approve the Report on the BOS's operations in 2025 and operational plan for 2026 <i>(Attached with Report No. 04/2026/AMV/BC-BKS)</i>			
Matter 05: To approve the Audited 2025 Financial Statements <i>(Attached with Proposal No. 05/2026/AMV/TTr-HĐQT)</i>			
Matter 06: To approve the 2025 profit distribution plan <i>(Attached with Proposal No. 06/2026/AMV/TTr-HĐQT)</i>			
Matter 07: To approve the remuneration plan for the BOD and the BOS in 2025 and the remuneration budget/plan for 2026 <i>(Attached with Proposal No. 07/2026/AMV/TTr-HĐQT)</i>			
Matter 08: To approve the selection of an auditing firm for the 2026 Financial Statements <i>(Attached with Proposal No. 08/2026/AMV/TTr-BKS)</i>			
Matter 09: To approve the update of the Company's business lines and sectors <i>(Attached with Proposal No. 09/2026/AMV/TTr-HĐQT)</i>			

* Shareholders must only mark one single box for each voting item.

Hanoi,, 2026

SHAREHOLDERS/AUTHORIZED REPRESENTATIVES

(Signature and full name)

(*) Notes:

- The voting matters and the counting of voting ballots for the contents submitted to Shareholders at the Meeting are specified in detail in the Regulations on the Organization of the 2026 AGM of Shareholders approved by the Meeting;
- Shareholders are kindly requested to read thoroughly the Regulations on the Organization of the 2026 AGM of Shareholders to exercise their voting rights at the Meeting;
- Shareholders shall select a voting choice (Approve or Disapprove or No opinion) for each item requested for voting;
- After completion, the Voting Ballot must be signed with the full name of the Shareholder and put into the Ballot Box under the instruction of the Vote Counting Committee.

This Voting Ballot is only applicable and used for voting on matters at the 2026 AGM of Shareholders of American Vietnamese Biotech Inc



THE SOCIALIST REPUBLIC OF VIETNAM
Independence – Freedom – Happiness

REGULATIONS ON THE ORGANIZATION
OF THE 2026 ANNUAL GENERAL MEETING OF SHAREHOLDERS
AMERICAN VIETNAMESE BIOTECH INC

PART I. GENERAL PROVISIONS

Article 1. Scope of application

These Regulations shall apply to the organization of the 2026 Annual General Meeting of Shareholders (hereinafter referred to as the “AGM”) of American Vietnamese Biotech Inc (hereinafter referred to as the “Company” or “AMV”).

Article 2. Regulated contents

These Regulations specify the rights and obligations of shareholders / authorized representatives attending the General Meeting, as well as the conditions and procedures for conducting the General Meeting.

Shareholders / authorized representatives attending the General Meeting are responsible for complying with the provisions of these Regulations, the Company's Charter, and applicable laws.

Article 3. Objectives of the General Meeting

1. To ensure the principles of transparency, fairness, and democracy.
2. To create favorable conditions for organizing and conducting the General Meeting of Shareholders, enabling the Company to promptly stabilize its business and production activities.

Article 4. Conditions for attendance

All shareholders named in the list of shareholders on the record date for attending the General Meeting shall have the right to attend the Meeting directly or authorize another person to attend the General Meeting.

PART II. RIGHTS AND OBLIGATIONS UPON ATTENDING THE GENERAL MEETING

Article 5. Rights and obligations of shareholders and authorized representatives attending the General Meeting

1. Ordinary shareholders have the right to attend, discuss, and vote on all matters within the authority of the Annual General Meeting of Shareholders; each ordinary share corresponds to one vote.
2. Shareholders entitled to attend the AGM may attend directly or authorize their representatives to attend. In the event that more than one authorized representative is appointed, the specific number of authorized shares for each representative must be clearly defined.
3. The power of attorney (Letter of Authorization) shall be made either in the form provided by the Company on its website or in accordance with civil law regulations. In case a shareholder prepares their own power of attorney, it must clearly state the following information:
 - a) Name of the authorizing shareholder, ID Card/Citizen ID Card/Passport number (for individuals) or tax code/establishment license number (for organizations);
 - b) Name of the authorized person, ID Card/Citizen ID Card/Passport number of the individual, or information of the authorized organization;
 - c) The number of authorized shares;
 - d) The content, scope, and duration of the authorization;
 - e) Signatures of both the authorizing party and the authorized party.

The power of attorney must ensure compliance with current legal regulations. In case of sub-authorization (re-authorization), the attendee must additionally present the original power of attorney of the shareholder or the authorized representative of the institutional shareholder (if not previously registered with the Company).

4. Upon arriving at the General Meeting, Shareholders or authorized representatives are kindly requested to present all of the following documents to complete the registration procedures:
 - The original of one of the valid personal identification documents: ID Card/Citizen ID Card/Passport, or other legal personal identification documents in accordance with the law; or access Level-2 electronic identification account via the National Electronic Identification Application (VNeID).
 - The original or certified true copy of: A valid Letter of Authorization.
 - The Meeting Invitation Notice issued by the Company.
5. Shareholders or authorized representatives shall only be officially permitted to attend and vote at the meeting after completing the registration procedures and proving their eligibility as valid shareholders or authorized representatives in accordance with these Regulations, the Charter of AMV, and legal regulations. In case a shareholder or representative arrives at the General Meeting after the opening time, they must still fully complete the registration procedures with the Organizing Committee. The Chairman of the Meeting is not responsible for pausing the General Meeting to perform this additional registration procedure, and the voting contents already conducted prior to that time shall not be affected by the late attendance of such shareholder or representative.

6. The voting ballot of the authorized person attending the meeting within the scope of authorization shall remain valid in one of the following cases:

- a) The authorizer has passed away, has limited civil capacity, or has lost civil capacity;
- b) The authorizer has rescinded the appointment of the authorization;
- c) The authorizer has rescinded the authority of the person executing the authorization;

The above provision shall not apply if the Company receives a notice of one of the aforementioned events 48 (forty-eight) hours prior to the opening time of the General Meeting of Shareholders or before the meeting is reconvened.

7. The Organizing Committee of the General Meeting of Shareholders shall publicly announce the Meeting Agenda. Opinions raised by shareholders or through authorized representatives at the General Meeting shall be discussed publicly and voted on by using the Voting Card and/or the Voting Ballot, depending on each specific matter.

8. Upon attending the General Meeting of Shareholders, shareholders and authorized representatives shall be issued:

- 01 Voting Card, to be used when speaking and voting on matters as requested by the Chairperson;
- 01 Voting Ballot, to be used for voting on matters that have been discussed or requested for opinions at the General Meeting;

These ballots/cards shall clearly state the shareholder code, the number of voting shares, and relevant information.

9. Shareholders / authorized representatives must strictly comply with the internal rules of the General Meeting, and respect the working results and the moderation of the Chairman of the Meeting.

10. Shareholders / authorized representatives are responsible for attending the General Meeting until the Chairman of the Meeting declares the closing of the General Meeting. If leaving the meeting before its conclusion for any reason, the shareholder / authorized representative must contact the Vote Counting Committee to return the Voting Ballot for matters to be voted on at the General Meeting. If they fail to notify upon leaving, the number of Voting Ballots of such Shareholder / authorized representative shall not be counted towards the voting results from the moment they leave the meeting.

Article 6. Rights and obligations of the Organizing Committee, the Shareholder Eligibility Verification Sub-committee, and the Vote Counting Committee

- 1. The Organizing Committee of the General Meeting shall be established under the decision of the Chairman of the Meeting. The Organizing Committee may set up sub-committees to assist during the organization process of the General Meeting.
- 2. The Shareholder Eligibility Verification Sub-committee shall be appointed by the Organizing Committee. The Shareholder Eligibility Verification Sub-committee is responsible for

verifying the eligibility of shareholders or their authorized representatives to attend the meeting based on the documents they present, summarizing the verification results, and reporting to the General Meeting on the eligibility verification results of the attending shareholders. In the event that an attendee does not possess full eligibility to attend the General Meeting, the Shareholder Eligibility Verification Sub-committee has the right to recommend the refusal of such person's right to attend, and recommend the refusal to issue the Voting Card, Voting Ballot, and Meeting materials to that person.

3. The Vote Counting Committee consists of 03 members, including 01 Head and 02 members, who are nominated by the Chairman of the Meeting and submitted to the Annual General Meeting for voting and approval at the meeting. To support the workload, in addition to the 02 official members of the Vote Counting Committee, the Head of the Vote Counting Committee may appoint additional personnel to coordinate and assist in the work.

The Vote Counting Committee is responsible for counting the Voting Cards and Voting Ballots during the process of collecting shareholders' votes and maintaining general supervision throughout the duration of the AGM.

Regarding the voting on contents at the General Meeting, the Committee shall:

- Guidance shareholders and their authorized representatives on how to use the Voting Cards and Voting Ballots;
- Collect the Voting Cards and Voting Ballots after the conclusion of the General Meeting;
- Count the number of Voting Ballots and Voting Cards by each category: approve, disapprove, and no opinion, and report the voting results for the Chairman of the Meeting to announce before the General Meeting.

Article 7. Chairman and Secretariat of the Meeting

1. The Chairman of the BOD shall serve as the Chairman of the Annual General Meeting. In the event that the Chairman of the BOD is absent or temporarily incapacitated, the remaining members of the BOD shall elect one person among themselves to act as the chairman of the meeting on a majority principle. If a chairman cannot be elected, the Head of the BOS shall moderate the Meeting so that the General Meeting can elect a chairman for the meeting among the attendees, and the person with the highest number of votes shall serve as the Chairman of the Meeting.
2. The decisions of the Chairman of the Meeting regarding matters of order, procedures, or events arising outside the agenda of the General Meeting shall be final and binding.
3. The Chairman of the Meeting has the right to take necessary and reasonable measures to moderate the meeting in an orderly manner, in accordance with the approved agenda, and to reflect the wishes of the majority of the attendees.
4. The Chairman of the Meeting has the right to adjourn a General Meeting that already has a sufficient number of registered attendees for a maximum of no more than 03 (three) working

days from the scheduled opening date, and may only adjourn the meeting or change the meeting venue in accordance with the cases specified in Clause 7, Article 20 of the Company's Charter.

5. The Secretariat of the Meeting shall be appointed by the Chairman of the Meeting. The Secretariat shall perform supportive tasks as assigned by the Chairman of the Meeting, and truthfully and accurately record the contents of the General Meeting in the Meeting Minutes and Resolutions of the General Meeting.

PART III. PROCEDURES FOR CONDUCTING THE GENERAL MEETING

Article 8. Conditions for conducting the General Meeting

1. The General Meeting of Shareholders shall be conducted when the number of attending shareholders represents more than 50% of the total number of voting shares.
2. In the event that the first meeting is unqualified to be conducted in accordance with Clause 1 of this Article, the second General Meeting of Shareholders shall be conducted when the number of attending shareholders represents 33% or more of the total number of voting shares. The timeline for sending the second meeting invitation notice shall comply with the Charter of AMV.
3. In the event that the second meeting is unqualified to be conducted in accordance with Clause 2 of this Article, the third General Meeting of Shareholders shall be conducted regardless of the total number of voting shares held by the attending shareholders. The timeline for sending the third meeting invitation notice shall comply with the Charter of AMV..

Article 9. Methods for conducting the General Meeting

1. The General Meeting shall discuss and vote to approve the agenda and contents of the meeting immediately after completing the procedures to legally convene the meeting.
2. The General Meeting shall proceed sequentially in accordance with the Meeting Agenda and conduct discussions prior to voting to approve the matters within the aforementioned contents. The approval of each item at the General Meeting shall be executed in accordance with Article 11 of these Regulations.

Article 10. Principles of speaking at the General Meeting

1. Shareholders who wish to propose any request at the 2026 Annual General Meeting of Shareholders must adhere to the following principles:
 - Shareholders are only permitted to contribute opinions during the discussion session of the General Meeting.
 - Shareholders must raise their Voting Cards to request permission from the Chairman of the Meeting and may only speak after being permitted by the Chairman of the Meeting. Only one shareholder has the right to speak at any given time.
 - In the event that multiple shareholders wish to speak at the same time, the Chairman of the Meeting shall sequentially invite each shareholder to present their opinions.

- The Chairman of the Meeting reserves the right to interrupt a shareholder's presentation if deemed necessary.
 - All contributions or queries shall be aggregated and addressed sequentially.
2. Proposals made by shareholders must satisfy the following conditions:
- Do not restate matters that have been previously addressed.
 - Be concise, clear, and focused directly on the core topics of discussion, in alignment with the approved Meeting Agenda.
 - The content of the proposal must not violate the law, relate to personal matters, or exceed the corporate authority of the enterprise.

Article 11. Voting and approval of Resolutions at the Annual General Meeting of Shareholders

1. Voting methods:
- a) Shareholders may vote to approve matters through the following methods:
- Voting directly at the General Meeting using Voting Cards and Voting Ballots;
 - Voting by appointing a valid authorized representative to attend the meeting; in which case, the authorized representative shall attend the General Meeting and vote in the same manner as a shareholder attending directly.
- b) Shareholders and Authorized Representatives shall exercise their voting rights at the 2026 Annual General Meeting of Shareholders of AMV by using Voting Cards and Voting Ballots.
- Voting Cards and Voting Ballots are pre-printed in accordance with the forms provided by the Organizing Committee, bearing the seal of American Vietnamese Biotech Inc, and issued to Shareholders / Authorized Representatives upon attending the General Meeting. The Voting Cards and Voting Ballots contain information regarding the shareholder code, the number of shares held by the Shareholder or the Shareholder's Representative attending the General Meeting.
 - Shareholders / Authorized Representatives shall use the Voting Cards to vote on matters requested for direct voting by raising the Voting Cards at the General Meeting.
 - Apart from matters requested for direct voting by raising Voting Cards at the General Meeting, for the contents of the Reports and Proposals, Shareholders shall vote by selecting their voting choices (Approve, Disapprove, No opinion) on the Voting Ballots, signing for confirmation, and submitting them back to the Vote Counting Committee.
- c) The General Meeting shall vote on each matter within the agenda sequentially. For each matter requiring a vote at the General Meeting, the Chairman of the Meeting shall request the voting to be conducted 03 times in the following sequence:
- First time: Voting for Approve.
 - Second time: Voting for Disapprove.
 - Third time: Voting for No opinion.

Each Shareholder or Authorized Representative (01 person) is only permitted to vote 01 time (*Approve or Disapprove or No opinion*) for the same matter requiring a vote at the General Meeting.

✓ *For direct voting by raising Voting Cards:* Any shareholder who does not raise their Voting Card in all 03 times the Chairman of the Meeting requests opinions on that content (Approve, Disapprove, No opinion) shall be deemed to Approve that content.

✓ *For voting on the contents of the Reports and Proposals by selecting voting choices on the Voting Ballots:* Shareholders shall mark a “✓” or “X” in the appropriate box on the Voting Ballot.

- A Voting Ballot is considered valid in the following cases:
 - + It is a Voting Ballot issued by the Vote Counting Committee of the General Meeting, bearing the seal of American Vietnamese Biotech Inc;
 - + The Voting Ballot is not torn;
 - + The voting content is not erased, scraped, or modified;
 - + A valid voting content is one where the Shareholder explicitly selects 1 out of the 3 boxes: Approve or Disapprove or No opinion;
 - + In the event that a Shareholder does not mark any of the 3 boxes for a particular voting item, it shall be deemed as Approve and considered valid for that voting item.
- A Voting Ballot and its voting content are considered invalid in one of the following cases:
 - + ~~The Voting Ballot was not issued by the Organizing Committee~~ of the General Meeting and does not bear the seal of American Vietnamese Biotech Inc;
 - + The Voting Ballot is torn, erased, or modified in terms of the information on the Ballot;
 - + The Voting Ballot does not bear the signature of the shareholder or the authorized representative of the shareholder;
 - + The shareholder marks 2 or more boxes for the same voting item, or the ballot contains erasures resulting in unclear choices, it shall be considered invalid for that specific voting item;
 - + The Voting Ballot is submitted to the Organizing Committee after the voting session has concluded and the Ballot Box has been sealed.
- 2. A Resolution on the following contents shall be approved if it is voted for by a number of shareholders representing **65% (sixty-five percent)** or more of the total voting shares of all attending and voting shareholders at the meeting, except for the cases specified in Clauses 3, 4, and 6, Article 148 of the Law on Enterprises:
 - a) Classes of shares and the total number of shares of each class;
 - b) Change of business lines and sectors;
 - c) Change of the company's management organizational structure;

- d) Investment projects or sale of assets with a value equal to or greater than 35% of the total asset value recorded in the Company's most recent Financial Statements, unless the Company's Charter stipulates another percentage or value;
 - e) Reorganization or dissolution of the company.
3. Resolutions shall be approved after being voted for by a number of shareholders holding more than **50% (fifty percent)** of the total voting shares of all attending and voting shareholders at the meeting, except for the cases specified in Clause 2 of this Article and Clauses 3, 4, and 6, Article 148 of the Law on Enterprises.
4. Resolutions of the General Meeting of Shareholders approved by 100% of the total voting shares are lawful and effective even when the sequence and procedures for convening the meeting and approving such resolutions violate the provisions of the Law on Enterprises and the Company's Charter..

Article 12. Resolutions and Minutes of the 2026 Annual General Meeting of Shareholders

The General Meeting must be recorded in minutes with the main contents specified in Clause 1, Article 23 of the Company's Charter. The Minutes of the General Meeting must be completed and approved before the conclusion of the meeting. The Chairman of the Meeting and the Secretary, or other persons signing the meeting minutes, shall be jointly responsible for the truthfulness and accuracy of the contents of the minutes.

Resolutions, Minutes of the General Meeting, all documents attached to the Minutes (if any), and relevant materials enclosed with the meeting invitation notice must be disclosed in accordance with legal regulations on information disclosure in the securities market and must be archived at the Head Office of the Company.

PART IV. IMPLEMENTATION PROVISIONS

1. These Regulations consist of 4 parts and 12 articles, approved by the 2026 Annual General Meeting of Shareholders of **American Vietnamese Biotech Inc** on June 30, 2026, and shall take effect immediately upon approval to conduct the 2026 Annual General Meeting of Shareholders of AMV.
2. Shareholders and attendees of the General Meeting are responsible for implementing the provisions of these Regulations.

Recipients:

- *Company Shareholders;*
- *Board of Directors (BOD);*
- *Organizing Committee of the General Meeting;*
- *Archived: HR & Administration Dept.*

**ON BEHALF OF THE GENERAL MEETING OF
SHAREHOLDERS**

CHAIRMAN OF THE MEETING

REPORT ON THE PERFORMANCE OF THE BOARD OF DIRECTORS IN 2025 & THE OPERATIONAL ORIENTATION FOR 2026

To: The General Meeting of Shareholders of American Vietnamese Biotech Inc

The Board of Directors ("BOD") of American Vietnamese Biotech Inc ("the Company" or "AMV") respectfully submits to the General Meeting of Shareholders ("GMS") the performance of the BOD in 2025 and the operational orientation for 2026 as follows:

I. BUSINESS PRODUCTION AND OPERATION RESULTS IN 2025

Based on the 2025 business production and operation plan approved by the 2025 Annual General Meeting of Shareholders, the BOD assigned tasks to the Board of Management and specialized departments, while actively directing the execution and achieved the following results:

Unit: VND

No.	Indicator	2025 Plan	2025 Performance	Ratio compared to Plan
1	Consolidated revenue	240.000.000.000	159.996.502.630	66,67%
2	Consolidated profit after tax	45.000.000.000	(74.496.420.006)	-

(Source: Audited 2025 Consolidated Financial Statements)

In 2025, the Company's business production and operation activities were deployed against the backdrop of domestic and international economies continuing to experience significant fluctuations; the financial, monetary markets, and investment activities remained under pressure from inflation, rising capital costs, along with geopolitical uncertainties and global economic instability. The medical equipment and healthcare services sector in Vietnam also faced numerous challenges, such as a high dependence on imports, fierce competitive pressure from premium imported goods and FDI enterprises, high investment and operating costs, stricter legal requirements, and pressure regarding human resource quality and governance efficiency during operational expansion. With its role in strategic orientation and guidance, AMV strived to issue timely strategies to optimize profits and protect the rights of shareholders and investors. Accordingly, the business production and operation results for 2025 are as follows:

Based on the 2025 Consolidated Financial Statements, the Company recorded total consolidated revenue of 159,99 billion VND, equivalent to 66,67% of the revenue plan approved by the 2025 Annual General Meeting of Shareholders (240 billion VND). The consolidated profit after tax recorded a loss of 74,49 billion VND, which did not meet the planned profit after tax target of 45 billion VND.

The primary reason leading to the business production and operation results in 2025 failing to meet the set plan is that the Company implemented business strategy adjustments to restructure its product portfolio and concentrate resources on sectors with sustainable long-term development potential. Consequently, several product groups that previously contributed significant revenue and were heavily promoted in 2024 were no longer the development focus in 2025, leading to a decrease in revenue and business efficiency compared to the set plan.

II. PERFORMANCE OF THE BOARD OF DIRECTORS IN 2025

The BOD has operated in strict compliance with the spirit, responsibilities, and authorities prescribed by current legal regulations, the Company's Charter, and internal regulations and policies of the Company. The meetings of the BOD were maintained regularly with a sufficient number of attending members, ensuring that all members of the Board of Directors promptly updated themselves on events arising from the Company's operations. The BOD closely followed the orientation of the Resolution of the 2025 Annual General Meeting of Shareholders and the actual situation of the Company to direct, manage, and supervise implementation activities in accordance with the agreed contents of the Resolution.

1. Personnel Status

The Company's BOD currently operates with 3 members as follows:

No.	Full Name	Position	Date of Appointment	Date of Dismissal
1	Nakatani Yoshitaka	Chairman of the BOD	29/07/2025	-
2	Dang Nhi Nuong	Member of the BOD	29/07/2025	-
3	Le Khanh Nguyen	Independent Member of the BOD	29/07/2025	-

2. Main Activities of the Board of Directors in 2025

In 2025, the BOD organized 14 meetings to deploy, consider, and resolve issues approved by the 2025 Annual General Meeting of Shareholders and other matters within its authority. The performance of the BOD is reflected through the contents discussed and resolved at face-to-face meetings or via written ballots. The meeting attendance rates were as follows:

No.	Full Name	Number of BOD Meetings Attended	Attendance Rate	Reason for Absence
1	Nakatani Yoshitaka	14/14	100%	-
2	Dang Nhi Nuong	14/14	100%	-

No.	Full Name	Number of BOD Meetings Attended	Attendance Rate	Reason for Absence
3	Le Khanh Nguyen	14/14	100%	-

Accordingly, the BOD issued and disclosed information for 14 Resolutions:

No.	Resolution/ Decision No.	Date	Content	Approval Rate
1	0601/2025/NQ-HĐQT	06/01/2025	On the transfer of capital contribution at Phu Tho Obstetrics and Pediatrics Hospital from Sara Vietnam Joint Stock Company	100%
2	0701/2025/NQ-HĐQT	07/01/2025	On the termination of operations of the Representative Office	100%
3	1701/2025/NQ-HĐQT	17/01/2025	On the second transfer of capital contribution at Phu Tho Obstetrics and Pediatrics Hospital from Sara Vietnam Joint Stock Company	100%
4	2502/2025/NQ-HĐQT	25/02/2025	On changing the payment schedule for the 2019 cash dividend	100%
5	2502.01/2025/NQ-HĐQT	25/02/2025	On the divestment of investment capital at Vietnam National Software Production Joint Stock Company	100%
6	2403/2025/NQ-HĐQT	24/03/2025	On extending the timeline for organizing the 2025 Annual General Meeting of Shareholders	100%
7	1604/2025/NQ-HĐQT	16/04/2025	On the premature withdrawal of capital contribution at Phu Tho Obstetrics and Pediatrics Hospital	100%
8	2904/2025/NQ-HĐQT	29/04/2025	On changing the service provider for the audit of the Company's 2024 Financial Statements	100%
9	1106/2025/NQ-HĐQT	11/06/2025	On changing the Chief Accountant of the Company	100%

No.	Resolution/ Decision No.	Date	Content	Approval Rate
10	0307/2025/NQ-HĐQT	03/07/2025	On approving the plan to organize the 2025 Annual General Meeting of Shareholders for the second time	100%
11	3007/2025/NQ-HĐQT	30/07/2025	On approving the personnel structure of the Board of Directors for the 2025-2030 term and changing the branch address	100%
12	3007.01/2025/NQ-HĐQT	30/07/2025	On signing the contract for the audit of the Company's 2025 Financial Statements	100%
13	1710/2025/NQ-HĐQT	17/10/2025	On changing the Chief Accountant of the Company	100%
14	2612/2025/NQ-HĐQT	26/12/2025	On approving a loan at Capella Group Joint Stock Company	100%

In which, the main contents authorized by the 2025 Annual General Meeting of Shareholders to the BOD for execution include:

● **Regarding the selection of an auditing firm to perform the audit and review of the Financial Statements for the 2025 fiscal year**

Implementing Annual GMS Resolution No. 2907/2025/NQ-ĐHĐCĐ dated 29/07/2025, the BOD met and approved Resolution No. 3007.01/2025/NQ-HĐQT dated 30/07/2025 and Resolution No. 0904/2026/NQ-HĐQT dated 09/04/2026 regarding the signing of contracts for the review and audit of the Company's Financial Statements in 2025. In which:

- The semi-annual consolidated financial statements for the first 6 months of the fiscal year ended 31/12/2025 and the semi-annual separate financial statements for the first 6 months of the fiscal year ended 31/12/2025 were reviewed by Nhan Tam Viet Auditing Company Limited;
- The consolidated financial statements for the fiscal year ended 31/12/2025 and the separate financial statements for the fiscal year ended 31/12/2025 were audited by International Auditing and Valuation Company Limited.

● **Regarding the adjustment of the timeline for cash dividend payment**

On January 19, 2026, the Board of Directors issued Resolution No. 1901/2026/NQ-HĐQT regarding the adjustment of the timeline for cash dividend payment. Accordingly, the expected payment schedules for Phase 1 and Phase 2 were adjusted to January 28, 2027 and July 28, 2027, respectively. The adjustment of the dividend payment timeline aims to ensure capital balance for business production, operations, investment in key projects, and to maintain the Company's

financial stability. Concurrently, the slower-than-expected recovery progress of certain customer receivables affected the cash flow plan.

3. Remuneration, operating expenses, and other benefits of the Board of Directors and the Director

The total 2025 income of the Board of Directors and the Director of the Company was 261,5 million VND, with specific details as follows:

No.	Full Name	Position	Total Income (VND)
1	Nakatani Yoshitaka	Chairman of the BOD	0
2	Dang Nhi Nuong (*)	Member of the BOD	0
		Director	261.500.000
3	Le Khanh Nguyen	Independent Member of the BOD	0
Total			261.500.000

(Source: Audited 2025 Consolidated Financial Statements)

(*) Ms. Dang Nhi Nuong is a member of the BOD concurrently holding the position of Director; the Company does not pay remuneration for her role as a BOD member but pays salary in accordance with the Labor Contract and internal regulations of the Company.

4. Supervision Results regarding the Board of Management and Other Executives

Pursuant to the Company's Charter, the Operational Regulations of the BOD, and the Internal Regulations on Corporate Governance, the BOD successfully performed its functions and duties in supervising the Board of Management and other executives in 2025 as follows:

- Supervising the business production and operation management to ensure strict alignment with the strategic orientation set by the BOD and approved by the GMS;
- Chairing, directing, and successfully organizing the 2025 Annual General Meeting of Shareholders;
- Attending all meetings to capture the Company's situation and business orientation, and issuing timely Resolutions/Decisions for the Board of Management to implement;
- Approving the policy for premature withdrawal of capital contribution at Phu Tho Obstetrics and Pediatrics Hospital;
- Supervising the preparation of the 2024 Financial Statements and the Quarterly Financial Statements in 2025;
- Cooperating with the Board of Supervisors in monitoring the Board of Management's direction of the Company's daily business operations;
- Supervising the activities of the Board of Management and other executives to ensure compliance with the Law on Enterprises and the Company's Charter.

Through supervision activities, the BOD notes that the Board of Management and other executives have fundamentally performed their assigned functions, duties, and authorities

properly, proactively cooperating, reporting, and providing timely information to the BOD to serve the Company's governance and management. The Board of Management seriously implemented the Resolutions of the GMS and the BOD, while complying with legal regulations, the Company's Charter, and internal regulations during corporate operation management. Furthermore, the close coordination among departments and divisions within the company contributed to creating stability and sustainability in the Company's operations.

Although the 2025 business operation results did not meet the set plan due to the impacts of general economic and market difficulties, the BOD recognizes the efforts of the Board of Management and the executive team in management and administration, which contributed to maintaining stable operations and ensuring the Company's operational safety.

5. General Evaluation of the BOD's Performance

- BOD members coordinated closely, promptly, and regularly with the Board of Management in directing the execution of GMS and BOD Resolutions for the Company.
- All decision-making matters of the BOD were thoroughly discussed by members, fully and promptly notified, and compliant with current legal regulations and the Company's Charter.
- Proposals from the executive Board of Management were studied, discussed, and given timely directions by BOD members.
- The Company fully and promptly complied with GMS Resolutions and legal regulations.

6. Report on Transactions between AMV and Related Parties

6.1. Report on transactions between AMV, AMV's subsidiaries, companies controlled by AMV with 50% or more of charter capital, and BOD members or their related persons

None.

6.2. Report on transactions between AMV and companies in which a BOD member is a founding member or enterprise manager during the most recent 03 years prior to the transaction date

None.

III. OPERATIONAL ORIENTATION FOR 2026

In 2026, against the backdrop where the Vietnamese economy is expected to maintain its growth momentum but still faces numerous challenges from global economic fluctuations, increasing competitive pressure, and rapid changes in market demand. In this context, the Company will experience certain impacts from industry competition in particular and objective factors in general; although many fluctuations remain latent, new opportunities are also emerging.

To proactively adapt to the aforementioned opportunities and challenges, the Board of Directors defines the core objective as consolidating financial capacity, improving operational efficiency, and creating a foundation for sustainable long-term growth, enhancing governance efficiency, and accompanying the Board of Management in deploying the Company's development strategy. Specifically, the BOD sets out the main operational orientations as follows:

➤ **Market Development and Business Expansion Orientation**

- Closely monitor market developments to build and deploy appropriate business strategies aimed at maximizing operational efficiency and enhancing the Company's competitive edge.
- Proactively seek and develop potential customer sources, expand the partner network, and ensure the maintenance of stable business operations.
- Continue expanding the scope of operations across all three regions (North – Central – South) and effectively exploit business opportunities in each locality.
- Continue investing in and expanding business sectors, accelerate the completion of ongoing projects, and invest in upcoming new projects.

➤ **Governance Capacity and Human Resource Quality Enhancement**

- Review, update, and improve internal regulations and workflows to enhance supervision and management efficiency. Concurrently, perfect the governance system towards a professional and transparent direction, aligned with international practices and legal regulations.
- Strengthen supervision over the activities of the Board of Management, ensuring that the execution of business strategies aligns with the GMS's orientation.
- Organize full periodic and extraordinary BOD meetings, ensuring that decisions are issued promptly and within the proper authority.
- Enhance human resource quality and the professionalism of the company's officers and employees, training human resources with a long-term vision, and dispatching technical officers and employees to participate in overseas training courses.

➤ **Efficiency Improvement and Sustainable Development**

- Continuously improve the quality of products and services to better meet customer needs.
- Implement strict cost management and efficiently utilize resources to enhance business production and operation efficiency.
- Pay attention to the material and spiritual life of employees, ensuring stable employment and building a professional, cohesive working environment.

Accordingly, the BOD sets out the 2026 business plan as follows:

Unit: VND

No.	Indicator	2025 Performance	2026 Plan
1	Consolidated revenue	159.996.502.630	360.000.000.000
2	Consolidated profit after tax	(74.496.420.006)	70.000.000.000

The above is the report of the Board of Directors of American Vietnamese Biotech Inc regarding the performance in 2025 and the operational orientation for 2026.

Respectfully submitted to the General Meeting of Shareholders for consideration and approval.

Respectfully./.

Recipients:

- GMS;
- BOD, BOS, BOM;
- Archived: Admin.

ON BEHALF OF THE BOARD OF DIRECTORS

CHAIRMAN OF THE BOD



NAKATANIYOSHITAKA

C.T.C.P

**REPORT ON THE PERFORMANCE OF THE INDEPENDENT MEMBERS
OF THE BOD AND THE EVALUATION RESULTS OF THE BOD’S
OPERATIONS IN 2025**

(Reporter: Mr. Le Khanh Nguyen – Independent Member of the BOD)

To: The General Meeting of Shareholders of American Vietnamese Biotech Inc

In accordance with current legal regulations, the Company’s Charter, and internal regulations regarding the responsibilities of independent members of the Board of Directors (“BOD”), I – Le Khanh Nguyen, an independent member of the BOD of American Vietnamese Biotech Inc (“the Company” or “AMV”), respectfully submit to the General Meeting of Shareholders (“GMS”) the report on my activities executed in 2025 and the evaluation results of the BOD’s operations in 2025 as follows:

I. PERFORMANCE OF THE INDEPENDENT MEMBER OF THE BOD IN 2025

● **Participation in BOD meetings:**

- Number of BOD meetings attended: 14/14.
- Attendance rate: 100%.

● **Other activities:**

- Fully exercised the roles of providing independent advice, evaluation, and supervision over the BOD’s activities in compliance with current legal regulations, the Company’s Charter, and internal Regulations;
- Ensured balance in the decision-making process, contributing to safeguarding the rights and interests of shareholders;
- Proposed and participated in establishing procedures to enhance corporate governance efficiency in alignment with best practices;
- Assumed an independent role in evaluating the performance of the Board of Management, ensuring transparency and accountability across the entire governance system.

II. EVALUATION RESULTS OF THE BOD’S OPERATIONS IN 2025

Based on continuous monitoring and evaluation of the Company’s BOD activities throughout 2025, I would like to present the following key assessments:

● **Assessment of compliance and governance**

- The BOD fully exercised its functions, duties, and authorities in accordance with legal regulations, the Company's Charter, and internal regulations. Governance activities were implemented in a transparent, prudent manner and aligned with the Company's sustainable development orientation.
- In 2025, the BOD maintained the organization of meetings, issued resolutions, and deployed governance tasks in strict compliance with the correct sequence, competence, and applicable regulations. Concurrently, the BOD focused on enhancing corporate governance quality.

● **Assessment of the BOD's operational efficiency**

- The BOD performed effectively in its role of strategic orientation and supervision of the Company's activities. Key decisions related to business production, investment, finance, and corporate governance were reviewed, discussed, and issued in a timely manner based on thorough information analysis and assessment of relevant risk factors.
- Amidst challenging market fluctuations, the BOD demonstrated its governance role at a strategic level, ensuring a balance between growth targets and risk control requirements, thereby contributing to maintaining stable operations and laying the foundation for the Company's long-term development.

● **Assessment of supervision over the Board of Management of the BOD**

- Supervision over the Board of Management was carried out regularly by the BOD through periodic reporting systems and reviews of the business plan implementation status .
- The BOD promptly monitored and evaluated the execution of approved resolutions and orientations, while providing appropriate directives to ensure that management activities were executed in alignment with the Company's goals and orientations.

● **Assessment of control over related-party transactions of the BOD**

- HĐQT đã chú trọng công tác kiểm soát các giao dịch với bên liên quan, bảo đảm việc xem xét và phê duyệt các giao dịch được thực hiện theo đúng quy định của pháp luật, Điều lệ Công ty và các quy định nội bộ có liên quan.
- Các giao dịch phát sinh được theo dõi và giám sát nhằm hạn chế xung đột lợi ích, đồng thời bảo đảm tính minh bạch và lợi ích chung của Công ty và cổ đông.

● **Assessment of the remuneration and expense policy of the BOD**

- The remuneration and operational expense policy of the BOD was implemented in accordance with legal regulations, the Company's Charter, and Resolutions of the GMS.

From the perspective of an Independent Member of the BOD, I assess that the BOD successfully fulfilled its role in governance, strategic orientation, and operational supervision of the Company in 2025 according to its assigned functions and duties. Throughout its operations, the BOD reviewed and balanced business objectives and investment plans, contributing to

maintaining the Company's operations in alignment with development orientations and governance requirements in each period.

The above is the full content of the Report on the performance of the Independent Members of the BOD and the evaluation results of the BOD's operations in 2025.

Respectfully submitted to the General Meeting of Shareholders for consideration and approval./.

Recipients:

- *General Meeting of Shareholders (GMS);*
- *BOD, BOS, Board of Management;*
- *Archived: Admin.*

INDEPENDENT MEMBER OF THE BOD



LE KHANH NGUYEN

AMERICAN VIETNAMESE
BIOTECH INC

-----oOo-----

No.: 03/2026/AMV/BC-BGD

THE SOCIALIST REPUBLIC OF VIETNAM
Independence – Freedom – Happiness

-----oOo-----

Hanoi, June 08, 2026

REPORT ON THE 2025 BUSINESS PERFORMANCE BY THE BOARD OF MANAGEMENT AND THE 2026 BUSINESS PLAN

To: The General Meeting of Shareholders of American Vietnamese Biotech Inc

The Board of Management ("BOM") of American Vietnamese Biotech Inc ("the Company" or "AMV") respectfully submits to the General Meeting of Shareholders ("GMS") the business production and operation results for 2025 and the plan for 2026 as follows:

I. BUSINESS OPERATION RESULTS IN 2025

1. Evaluation of the 2025 Business Production and Operation Results:

In 2025, the Company's business production and operation activities were deployed against the backdrop of domestic and international economies continuing to experience significant fluctuations; the financial, monetary markets, and investment activities remained under pressure from inflation, rising capital costs, along with geopolitical uncertainties and global economic instability. The medical equipment and healthcare services sector in Vietnam also faced numerous challenges, such as a high dependence on imports, fierce competitive pressure from premium imported goods and FDI enterprises, high investment and operating costs, stricter legal requirements, and pressure regarding human resource quality and governance efficiency during operational expansion.

In that context, the Board of Management focused on deploying solutions to maintain stable business operations, control costs, and step-by-step expand the Company's operational sectors. The demand for medical products, equipment, and healthcare services continued to show an upward trend alongside the improvement in people's income and healthcare needs, thereby creating favorable conditions for the Company to maintain its business operations in the medical equipment and medical services sectors. Throughout its operations, the Company continued to maintain and develop cooperative relationships with partners and customers in the medical field, such as Phu Tho Province General Hospital, Phu Tho Obstetrics and Pediatrics Hospital, and several other medical units.

Although the Board of Management proactively reviewed operations, balanced resources, and deployed solutions to maintain business production and operations, the execution results in 2025 still did not meet the set business plan due to the impacts of the business environment over the past year, which remained full of difficulties and fluctuations. In the coming period, the Company will continue to review operations, control costs, improve governance efficiency, and step-by-step seek investment and business opportunities that align with the Company's development orientation.

2. Summary of Several Major Performance Indicators in 2025

➤ Performance Results compared to the 2025 Plan

Implementing the Company's business production and operation plan for 2025, the business results achieved by the Company are as follows:

Unit: VND

No.	Indicator	2025 Plan	2025 Performance	Ratio compared to Plan
1	Consolidated revenue	240.000.000.000	159.996.502.630	66,67%
2	Consolidated profit after tax	45.000.000.000	(74.496.420.006)	-

(Source: Audited 2025 Consolidated Financial Statements)

➤ Performance Results compared to the 2024 Performance Results

Unit: VND

No.	Indicator	2025 Plan	2025 Performance	Increase/ Decrease Rate
1	Consolidated revenue	310.354.603.848	159.996.502.630	(93,98%)
2	Consolidated profit after tax	(13.065.198.309)	(74.496.420.006)	-

(Source: Audited 2025 Consolidated Financial Statements)

➤ Asset Status

Unit: VND

No.	Consolidated Indicator	1/1/2025	31/12/2025	Increase/ Decrease Rate
1	Short-term assets	951.892.884.765	661.718.343.088	(43,85%)
2	Long-term assets	1.003.747.749.992	1.221.484.122.791	17,83%
Total		1.955.640.634.757	1.883.202.465.879	(3,85%)

(Source: Audited 2025 Consolidated Financial Statements)

Total assets as of December 31, 2025, reached 1.883,202 billion VND, a decrease of 3,85% compared to that of January 1, 2025 (1.955,640 billion VND). In which:

- Short-term assets in 2025 decreased mainly due to a decline in short-term receivables from 882,737 billion VND (1/1/2025) to 600,709 billion VND (31/12/2025). In addition, the

provision value for doubtful short-term receivables increased from 22,394 billion VND to 68,144 billion VND.

- Long-term assets increased primarily due to an increase in long-term receivables from 61,988 billion VND to 187,642 billion VND. Concurrently, the company also increased its capital contribution investments in other entities and joint ventures/associates, leading to an increase in long-term financial investments from 621,833 billion VND to 730,720 billion VND.

➤ Liabilities Status

Unit: VND

No.	Consolidated Indicator	1/1/2025	31/12/2025	Increase/ Decrease Rate
1	Short-term liabilities	156.093.026.150	286.503.675.080	45,52%
2	Long-term liabilities	126.837.798.283	0	-
Total		282.930.824.433	286.503.675.080	1,25%

(Source: Audited 2025 Consolidated Financial Statements)

Total liabilities in 2025 increased from 282,93 billion VND to 286,50 billion VND, corresponding to an increase of 1,25%. The change in debt structure was mainly driven by the bond package VMH12101 worth 126,5 billion VND being reclassified from long-term liabilities to short-term liabilities as it approached its maturity date on January 7, 2026. Viet My Hospital Investment Joint Stock Company successfully completed the full payment of the principal and interest for this bond on January 7, 2026, in strict compliance with regulations.

2. Evaluation of Operational Sectors

2.1. Financial and Accounting Performance

- Strictly complying with the preparation of financial statements in accordance with accounting standards and performing timely information disclosure in compliance with regulations to ensure transparency for shareholders.
- Formulating measures for the efficient management and utilization of capital resources during business production and operations.
- Completing the restructuring of personnel to proactively handle work related to finance, accounting, and capital resources.

2.2. Information Disclosure Performance and Compliance with Securities Market Regulations

- Performing periodic and extraordinary information disclosure to provide timely and transparent information to shareholders in strict compliance with current legal regulations.
- Strictly and properly complying with regulations applicable to listed enterprises on the securities market.

II. BUSINESS PLAN FOR 2026

Based on the actual business production and operation situation in 2025 and the orientation of the BOD regarding the operational direction for 2026, AMV formulates the 2026 business plan with several targets as follows:

1. 2026 Business Plan Indicators

Unit: VND

No.	Indicator	2025 Performance	2026 Plan
1	Consolidated revenue	117.275.783.030	360.000.000.000
2	Consolidated profit after tax	222.606.600	70.000.000.000

Based on the 2025 business production and operation results recording a loss after tax of 74,49 billion VND, the Board of Management respectfully submits to the General Meeting of Shareholders to consider and approve the plan of no dividend payment and no appropriation to funds for the year 2025, in order to preserve capital and concentrate financial resources on investment activities, stabilizing business production, operations, and development investment in the coming period.

2. Core Tasks

In 2025, the medical supplies production and business market still faced difficulties and complexities. The Board of Management studied and evaluated the company's capacity and the specific market situation, thereby orienting the targets set for 2026 as follows:

- Deploying synchronous solutions to fulfill the revenue and profit targets approved by the GMS and the BOD.
- Closely monitoring market developments, proactively reviewing business activities to maintain stability in the Company's operations;
- Continuing to invest in and expand business sectors, accelerating the completion of ongoing projects, and investing in upcoming new projects;
- Strengthening corporate governance and management, controlling the implementation progress of projects, and concurrently reviewing the efficiency of resource utilization during operations;
- Enhancing human resource quality and the professionalism of the company's officers and employees, training human resources with a long-term vision, and dispatching technical officers and employees to participate in overseas training courses;
- Maintaining and improving the quality of products and services toward better meeting the requirements of customers and partners;
- Managing costs efficiently to ensure business performance;
- Ensuring employment and income for employees.

3. Solutions for Executing the 2026 Business Production and Operation Plan

To ensure that the Company's business production and operation activities closely follow the orientation and direction of the GMS and the BOD, the Board of Management proposes the deployment of several specific solutions as follows:

➤ **Focusing on Market Development and Revenue Generation**

- Strengthening the search for new customers and expanding the system to enhance market exploitation capabilities.
- Promoting sales activities, developing products and services that possess a competitive advantage and align with market demand.
- Proactively researching new business opportunities and expanding the scope of operations in potential territories.

➤ **Improving Management and Supervision Efficiency**

- Perfecting and standardizing the system of internal regulations and policies, drafting specialized guiding documents appropriate to the functions of each department/division, ensuring strict compliance with legal regulations and corporate governance standards.
- Enhancing the synthesis, analysis, and periodic evaluation of the business production and operation situation, serving as a basis for timely and accurate management decisions.
- Establishing flexible reporting mechanisms based on actual requirements, helping Company Leaders easily capture and coordinate work effectively.

➤ **Developing High-Quality Human Resources**

- Promoting internal training and enhancing professional and soft skills for the team of officers and employees.
- Strengthening the sense of responsibility, discipline, and professional attitude among all employees; utilizing work efficiency as the metric for evaluation, authorization, and assignment of responsibilities.

➤ **Applying Technology in Management and Service Provision**

- Continuing to invest in and upgrade the information technology infrastructure to serve management, administration, and interaction among departments.
- Accelerating the application of enterprise management software (ERP, CRM, HRM...), automated reporting tools, digital signatures, and document management systems – contributing to enhancing labor productivity and reducing administrative procedures.
- Step-by-step digitizing the customer service process, improving service experience, and increasing competitive value in the market.

The above is the content of the report on the 2025 business performance and the 2026 business plan by the Board of Management.

Respectfully submitted to the General Meeting of Shareholders for consideration and approval.

Respectfully./.

Recipients:

- GMS;
- BOD, BOM, BOS;
- Archived: Admin.



**REPORT ON THE BOS'S OPERATIONS IN 2025
AND OPERATIONAL PLAN FOR 2026**

To: The General Meeting of Shareholders of American Vietnamese Biotech Inc

The Board of Supervisors ("BOS") of American Vietnamese Biotech Inc ("the Company" or "AMV") respectfully submits to the Annual General Meeting of Shareholders ("GMS") the operational performance in 2025 and the operational plan for 2026 as follows:

1. OPERATIONAL PERFORMANCE OF THE BOARD OF SUPERVISORS IN 2025

1.1. Membership Structure of the Board of Supervisors

No.	Full Name	Position	Date of Appointment	Date of Dismissal
1	Le Thi Huong	Head of the BOS	29/07/2025	-
2	Nguyen Huong Giang	Member of the BOS	29/07/2025	-
3	Vu Thu Thuy	Member of the BOS	30/06/2025	29/07/2025
4	Le Huu Tri	Member of the BOS	29/07/2025	-

1.2. Main Activities of the Board of Supervisors

In 2025, the Board of Supervisors performed its functions and duties in accordance with the regulations of the law, the Company's Charter, and relevant internal regulations. BOS members deployed supervision activities over the management and administration performance of the Board of Directors and the Board of Management; and supervised compliance with legal regulations, the Company's Charter, GMS Resolutions, and the Company's internal rules and regulations. Specifically as follows:

- Monitoring and reviewing the business production, operation, and financial status, as well as the implementation of the Company's resolutions and decisions through periodic reports, specialized documents, and working meetings with the Board of Directors, the Board of Management, and related departments.
- Appraising the completeness, legality, and truthfulness of the company's annual and semi-annual business performance reports and financial statements, as well as the reports evaluating the management performance of the BOD, and submitting the appraisal reports at the Annual GMS meeting.

- Reviewing contracts and transactions with related persons within the approval authority of the BOD or GMS, and providing recommendations on contracts and transactions that require approval from the BOD or GMS.
- Attending all meetings of the BOD and the Management Team to monitor and evaluate the Company's operational performance, while contributing opinions on contents related to business operation orientation, corporate governance, financial management, and risk control, aiming to enhance governance efficiency and mitigate risks arising during operations.
- Maintaining coordination with the BOD, the Board of Management, and related departments in providing information and documents to serve inspection and supervision work in accordance with regulations.

1.3. Meetings of the Board of Supervisors

The Board of Supervisors organized 08 (eight) meetings with the full participation of all incumbent members to perform tasks related to the organization and operations of the BOS:

No.	Full Name	Number of Meetings Attended	Voting rate
1	Le Thi Huong	08/08	100%
2	Nguyen Huong Giang	08/08	100%
3	Vu Thu Thuy	06/06	100%
4	Le Huu Tri	02/02	100%

Accordingly, the main contents of the meetings are as follows:

- Summarizing the supervision of the implementation of GMS and BOD Resolutions by the members of the BOD, the Director, and other managers of the Company.
-
- Evaluating the supervision of the Company's compliance with legal regulations, the Company's Charter, and the Company's internal rules and regulations.
-
- Reviewing, discussing, and implementing contents related to perfecting the membership structure of the Board of Supervisors due to personnel changes in 2025, ensuring that the operations of the Board of Supervisors comply with legal regulations and the Company's Charter.
- Reaching a consensus on selecting the auditing firm to review the 2025 Financial Statements.

- Appraising the 2025 Financial Statements; reviewing the legality, reasonableness, truthfulness, and level of diligence in accounting practices and the presentation of financial statements.
- Supervising and urging the Board of Management and related departments to coordinate with the auditing firm to accelerate the audit progress, complete, and disclose the Financial Statements in strict compliance with legal regulations, and providing recommendations to mitigate delays in information disclosure.
- Supervising transactions with related parties, associates, and the information disclosure performance in accordance with current legal regulations.

1.4. Remuneration and Operating Expenses of the BOS and Each Supervisor in 2025

According to the remuneration payment plan for the BOS approved by the 2025 Annual GMS, the remuneration rates for the BOS are as follows:

No.	Position	Remuneration Rate (VND/person/month)
1	Head of the BOS	3.000.000
2	Head of the BOS	2.000.000

However, to share the difficulties with the Company, the BOS has unanimously agreed not to receive remuneration for the year 2025.

2. SUPERVISION RESULTS OF THE BOARD OF SUPERVISORS

2.1. Supervision Results regarding the Operational and Business Status of the Company

➤ Business Results

The Company's 2025 consolidated revenue reached approximately 159,99 billion VND, achieving 66,67% of the set plan (240 billion VND), representing a decrease of 93,98% compared to the 2024 consolidated revenue (310,35 billion VND);

The consolidated profit after tax recorded a loss of approximately 74,49 billion VND, failing to meet the set plan (45 billion VND).

➤ Financial Status

- Total assets as of December 31, 2025, reached 1.883,202 billion VND, a decrease of 3,85% compared to that of January 1, 2025 (1.955,640 billion VND). In which:

+Short-term assets in 2025 decreased mainly due to a decline in short-term receivables from 882,737 billion VND (1/1/2025) to 600,709 billion VND (31/12/2025). In addition, the provision value for doubtful short-term receivables increased from 22,394 billion VND to 68,144 billion VND.

+Long-term assets increased primarily due to an increase in long-term receivables from 61,988 billion VND to 187,642 billion VND. Concurrently, the company also increased its capital

contribution investments in other entities and joint ventures/associates, leading to an increase in long-term financial investments from 621,833 billion VND to 730,720 billion VND.

- Total liabilities in 2025 increased from 282,930 billion VND to 286,503 billion VND (an increase of 1,25%). During the year, the liability structure experienced a change when the bond outstanding balance VMH12101 worth 126,5 billion VND issued by Viet My Hospital Investment Joint Stock Company (a subsidiary of AMV) was reclassified from long-term liabilities to short-term liabilities as it approached its maturity date on January 7, 2026. After the end of the 2025 fiscal year, on January 7, 2026, Viet My Hospital Investment Joint Stock Company successfully completed the full payment of the principal and interest for this bond package in strict compliance with current legal regulations.

2.2. Supervision Results regarding the BOD and the Board of Management

➤ Regarding the Operations of the BOD

In 2025, to implement the Resolution of the 2025 Annual GMS, the BOD constantly and proactively followed market developments and the Company's actual business activities to issue strategic resolutions and decisions, orienting the operations of the Board of Management with the objective of fulfilling the 2025 business plan. Accordingly, the BOD conducted a total of 14 meetings and approved 14 corresponding Resolutions. However, up to the present, the overall economy has not yet achieved robust growth, and the risk of economic recession persists; nonetheless, the BOD and the Board of Management have operated highly proactively and achieved certain efficiencies.

In the BOD meetings in particular and the operations of the BOD in general, BOD members fully participated and worked with a high sense of responsibility, remaining ready to contribute constructive opinions to promptly issue correct and timely decisions serving the governance and business operations of the Company.

Through the supervision process, the BOS notes that the BOD has operated within its proper authority and duties as prescribed by legal regulations, the Company's Charter, and the Company's internal rules and regulations. The BOS has not detected any abnormal signs or violations in the governance and management activities of the BOD in general and individual BOD members in particular.

➤ Regarding the Operations of the Board of Management

During the management of business operations, the Board of Management provided periodic reports regarding the business performance status of the reporting month to the BOD and the BOS.

Through the supervision process, the BOS notes that the Board of Management has been proactive and flexible in following market developments to synchronously deploy multiple solutions regarding human resources, technology, products, customer orientation, and risk management with the highest goal of fulfilling the 2025 business plan, while maintaining the stable

and sustainable development of the Company's business operations. The BOS has not detected any abnormal signs or violations in the Company's management process by the Board of Management.

2.3. Appraisal Results of the Financial Statements in the 2025 Fiscal Year

The BOS performed periodic appraisals of the Company's Financial Statements in the 2025 fiscal year. Specifically:

- The financial statements fully reflected the business production, operation, and financial status of the Company. The recording, opening of accounting books, and classification of economic contents complied with the Vietnamese Accounting System and Standards issued by the Ministry of Finance.
- The reports presented truly and fairly, in all material respects, the financial position of the Company.
- The Company fully executed reporting and periodic information disclosure in accordance with current regulations on information disclosure in the securities market.

2.4. Results of Reviewing and Evaluating Transactions between AMV and Related Parties

- Regarding transactions between AMV, subsidiaries of AMV, and companies where AMV holds control of over 50% of the charter capital, with members of the BOD, the Director, other managers of the enterprise, and their related persons: No transactions occurred.
- Regarding transactions between AMV and companies where a member of the BOD, the Director, or other managers of the enterprise is a founding member or an enterprise manager during the most recent 03 years prior to the transaction date: No transactions occurred.
- Regarding the signing and execution of contracts and transactions with related persons: The Company executed them in strict compliance with current legal regulations. The details of these transactions are presented by the Company in the audited Consolidated Financial Statements for the fiscal year ended December 31, 2025, the 2025 Corporate Governance Report, and the 2025 Annual Report.

2.5. Results of Evaluating the Operational Coordination between the BOS and the BOD, the Board of Management, and Other Managers

The Board of Supervisors was fully invited to attend all meetings of the BOD. These meetings included monthly and quarterly reports from the Board of Management regarding business production and operation results, investment progress, and evaluation of the implementation rate of the Resolutions set forth by the General Meeting of Shareholders.

Resolutions/Decisions, Reports, and Proposals of the Board of Management were promptly sent to the BOS for acknowledgment and tracking.

In the exercise of its powers, the BOS ensured not to affect the governance activities of the BOD or the management activities of the Board of Management, and caused no disruption to the Company's business operations.

3. Operational Plan of the Board of Supervisors in 2026

In 2026, the Board of Supervisors will continue to promote its independent, proactive, and efficient supervisory role in checking and supervising the governance and management activities of the Company; concurrently providing timely advice and recommendations to enhance internal governance effectiveness and ensure legal compliance. The specific plan is as follows:

- Strengthening the compliance supervision of the Board of Management in accordance with legal regulations, the Company's Charter, GMS Resolutions, BOD Decisions, and the Company's internal rules and regulations. Concurrently, checking and supervising the execution results of targets and plans set forth in the meetings of the Board of Management.
- Performing periodic audits according to the audit plan approved by the BOD and extraordinary audits upon the request of the BOD.
- Regularly checking and supervising the activities of units within the Company and offering recommendations to perfect the Company's governance and risk management processes.
- Contributing to perfecting the enterprise risk management system in alignment with the Company's operational status and current legal regulations.
- Supervising the service quality of the Independent Auditing Firm during the audit periods of the 2025 fiscal year.
- Continuing to review contracts and transactions with related persons within the approval authority of the BOD or GMS, and providing recommendations on contracts and transactions that require approval from the BOD or GMS.
- Performing other tasks in accordance with the regulations set forth in the Operational Regulations of the Company's BOS..

The above is the operational report of the Board of Supervisors in 2025 and the plan for 2026.

Respectfully submitted to the General Meeting of Shareholders for consideration and approval.

Sincerely./.

Recipients:

- GMS;
- BOD, BOM, BOS;
- Archived: Admin.

ON BEHALF OF THE BOS

HEAD OF THE BOARD



LE THI HUONG

AMERICAN VIETNAMESE
BIOTECH INC

-----oOo-----

No.: 05/2026/AMV/TTr-HĐQT

THE SOCIALIST REPUBLIC OF VIETNAM
Independence – Freedom – Happiness

-----oOo-----

Hanoi, June 08, 2026

PROPOSAL OF THE BOARD OF DIRECTORS
On the approval of the Audited 2025 Financial Statements

To: The General Meeting of Shareholders of American Vietnamese Biotech Inc

- Pursuant to the Law on Enterprises No. 59/2020/QH14 approved by the National Assembly of the Socialist Republic of Vietnam on June 17, 2020, and its guiding legal documents;
- Pursuant to the Law on Securities No. 54/2019/QH14 approved by the National Assembly of the Socialist Republic of Vietnam on November 26, 2019, and its guiding legal documents;
- Pursuant to the Charter of American Vietnamese Biotech Inc.

The Board of Directors ("BOD") of American Vietnamese Biotech Inc ("the Company" or "AMV") respectfully submits to the General Meeting of Shareholders ("GMS") for approval the consolidated financial statements and separate financial statements for the fiscal year ended December 31, 2025, audited by International Auditing and Valuation Company Limited ("IAV"). Specifically including:

- Report of the Board of Management;
- Independent Auditors' Report;
- Audited Financial Statements: Balance Sheet; Income Statement; Cash Flow Statement; Notes to the Financial Statements.

Several Indicators in the 2025 Financial Statements:

Unit: VND

No.	Indicator	Separate Financial Statements	Consolidated Financial Statements
1	Total assets	1.626.562.939.696	1.883.202.465.879
2	Total liabilities	124.569.205.721	286.503.675.080
3	Owner's equity	1.501.993.733.975	1.596.698.790.799
4	Net revenue	25.762.745.204	159.667.164.759
5	Profit before tax	(42.910.980.816)	(73.701.068.332)
6	Lợi nhuận sau Profit after tax	(42.910.980.816)	(74.496.420.006)

The audited consolidated financial statements and separate financial statements for the

fiscal year ended December 31, 2025, have been uploaded and disclosed simultaneously in both Vietnamese and English in accordance with regulations on the Company's website: <https://amvibiotech.com/danh-muc/bao-cai-tai-chinh/>

Respectfully submitted to the Annual General Meeting of Shareholders for consideration and approval./.

Recipients:

- As above;
- Archived: Admin.

ON BEHALF OF THE BOARD OF DIRECTORS

CHAIRMAN OF THE BOD



NAKATANI YOSHITAKA



AMERICAN VIETNAMESE
BIOTECH INC

-----oOo-----

No.: 06/2026/AMV/TTr-HĐQT

THE SOCIALIST REPUBLIC OF VIETNAM
Independence – Freedom – Happiness

-----oOo-----

Hanoi, June 08, 2026

PROPOSAL OF THE BOARD OF DIRECTORS

On the approval of the 2025 profit distribution plan

To: The General Meeting of Shareholders of American Vietnamese Biotech Inc

- Pursuant to the Law on Enterprises No. 59/2020/QH14 approved by the National Assembly of the Socialist Republic of Vietnam on June 17, 2020, and its guiding legal documents for implementation;
- Pursuant to the Law on Securities No. 54/2019/QH14 approved by the National Assembly of the Socialist Republic of Vietnam on November 26, 2019, and its guiding legal documents for implementation;
- Pursuant to the Charter of American Vietnamese Biotech Inc;
- Based on the actual situation of the Company.

The Board of Directors ("BOD") of American Vietnamese Biotech Inc ("the Company" or "AMV") respectfully submits to the General Meeting of Shareholders ("GMS") for consideration and approval of the 2025 profit distribution plan.

Based on the audited Consolidated Financial Statements for the fiscal year ended December 31, 2025, the business results of the Company are recorded as follows:

No.	Consolidated Indicators	Value (VND)
1	Total accounting profit before tax in 2025	(73.701.068.332)
2	Current corporate income tax (CIT) expenses	795.351.674
3	Profit after corporate income tax in 2025	(74.496.420.006)

Since the Company recorded a loss in the 2025 fiscal year, the BOD proposes the GMS to approve the plan of no dividend payment and no appropriation to funds, in order to preserve capital and concentrate financial resources on investment activities and stabilizing business operations in the coming period.


Respectfully submitted to the Annual General Meeting of Shareholders for consideration and approval./.

Recipients:

- As above;
- Archived: Admin.

ON BEHALF OF THE BOARD OF DIRECTORS

CHAIRMAN OF THE BOD



NAKATANI YOSHITAKA

AMERICAN VIETNAMESE
BIOTECH INC

-----oOo-----

No.: 07/2026/AMV/TTr-HĐQT

THE SOCIALIST REPUBLIC OF VIETNAM
Independence – Freedom – Happiness

-----oOo-----

Hanoi, June 08, 2026

PROPOSAL OF THE BOARD OF DIRECTORS

On the remuneration plan for the BOD and the BOS in 2025 and the remuneration budget for 2026

To: The General Meeting of Shareholders of American Vietnamese Biotech Inc

- Pursuant to the Law on Enterprises No. 59/2020/QH14 approved by the National Assembly of the Socialist Republic of Vietnam on June 17, 2020, and its guiding legal documents for implementation;
- Pursuant to the Law on Securities No. 54/2019/QH14 approved by the National Assembly of the Socialist Republic of Vietnam on November 26, 2019, and its guiding legal documents for implementation;
- Pursuant to the Charter of American Vietnamese Biotech Inc;
- Based on the actual situation of the Company.

The Board of Directors ("BOD") of American Vietnamese Biotech Inc ("the Company" or "AMV") respectfully submits to the General Meeting of Shareholders ("GMS") for consideration and approval of the remuneration plan for the members of the BOD and the Board of Supervisors ("BOS") in 2025 and the remuneration budget for 2026 as follows:

1. Remuneration for the BOD and the BOS in 2025

According to the remuneration plan for the BOD and the BOS approved by the 2025 Annual General Meeting of Shareholders, the remuneration rates for the BOD and the BOS in 2025 were as follows:

No.	Position	Remuneration Rate (VND/person/month)
I	Board of Directors	
1	Chairman of the BOD	10.000.000
2	Member of the BOD	5.000.000
II	Board of Supervisors	
1	Head of the BOS	3.000.000
2	Member of the BOS	2.000.000

Based on the audited Consolidated Financial Statements for the fiscal year ended December 31, 2025, the Company recorded a loss of 74,49 billion VND. Therefore, to share the difficulties

with the Company, the BOD and the BOS have mutually agreed not to receive remuneration for the year 2025. In the case where a member of the BOD concurrently holds the position of Director, the Company does not pay BOD remuneration but instead pays salary in accordance with the Labor Contract and internal regulations of the Company; specifically, the salary of this BOD member is disclosed by the Company as a separate item in the 2025 Consolidated Financial Statements.

2. Remuneration budget for the BOD and the BOS in 2026

The BOD respectfully submits to the GMS the estimated remuneration for the BOD and the BOS in 2026 as follows:

No.	Position	Remuneration Rate (VND/person/month)
I	Board of Directors	
1	Chairman of the BOD	10.000.000
2	Member of the BOD	5.000.000
II	Board of Supervisors	
1	Head of the BOS	3.000.000
2	Member of the BOS	2.000.000

Respectfully submitted to the General Meeting of Shareholders for consideration and approval./.

Recipients:

- As above;
- Archived: Admin.

ON BEHALF OF THE BOARD OF DIRECTORS

CHAIRMAN OF THE BOD



NAKATANI YOSHITAKA

PROPOSAL OF THE BOARD OF SUPERVISORS

On the selection of an auditing firm for the 2026 Financial Statements

To: The General Meeting of Shareholders of American Vietnamese Biotech Inc

- Pursuant to the Law on Enterprises No. 59/2020/QH14 approved by the National Assembly of the Socialist Republic of Vietnam on June 17, 2020, and its guiding legal documents for implementation;
- Pursuant to the Law on Securities No. 54/2019/QH14 approved by the National Assembly of the Socialist Republic of Vietnam on November 26, 2019, and its guiding legal documents for implementation;
- Pursuant to the Charter of American Vietnamese Biotech Inc.

Based on the functions and duties of the Board of Supervisors ("BOS") in accordance with current legal regulations, the Company's Charter, and internal regulations of the Company, the BOS of American Vietnamese Biotech Inc ("the Company" or "AMV") respectfully submits to the General Meeting of Shareholders ("GMS") for the selection of an independent auditing firm to perform the audit and review of the 2026 Financial Statements, with specific details as follows:

1. Criteria for selecting the Independent Auditing Firm

The Board of Supervisors proposes the criteria for selecting the Independent Auditing Firm as follows:

- Operating legally in Vietnam and being included in the list of auditing organizations approved by the State Securities Commission to perform audits in accordance with securities laws and independent audit regulations;
- Possessing extensive auditing experience;
- Maintaining a strong reputation for audit quality;
- Having a team of highly qualified and experienced auditors;
- Meeting AMV's requirements regarding the scope and timeline of the audit;
- Offering a reasonable audit fee commensurate with the audit quality, based on the review of the audit fee proposals and the scope of the audit.

2. Proposal of the Board of Supervisors

Based on the aforementioned selection criteria, the Board of Supervisors respectfully proposes the auditing firms listed in the "*List of auditing firms approved to audit public interest*



entities in the securities sector for the year 2026” issued under Decision No. 902/QĐ-UBCK dated November 19, 2025, by the Chairperson of the State Securities Commission approving auditing enterprises and practicing auditors to perform audits for public interest entities in 2026 (Detailed list is provided in the Appendix attached with this Proposal). Accordingly, the Board of Supervisors proposes the GMS to:

- Authorize the Board of Directors ("BOD") to select one of the auditing firms from the aforementioned list to perform the audit and review of the Company's 2026 Financial Statements in compliance with securities and independent audit regulations.
- Assign the BOD to proactively adjust, supplement, remove, or replace any auditing firm in the selection list to align with the “List of auditing firms and auditors approved to audit public interest entities in the securities sector” issued and published by the State Securities Commission from time to time.

Respectfully submitted to the General Meeting of Shareholders for consideration and approval./.

Recipients:

- As above;
- Archived: Admin, BOD Office.

ON BEHALF OF THE BOS

HEAD OF THE BOARD



APPENDIX: LIST OF AUDITING FIRMS APPROVED TO AUDIT PUBLIC INTEREST ENTITIES IN THE SECURITIES SECTOR FOR THE YEAR 2026

(Attached with Proposal No. 08/2026/AMV/TTr-BKS)

No.	COMPANY NAME
1	KPMG Limited (KPMG)
2	AASC Auditing Firm Company Limited (AASC)
3	A&C Auditing and Consulting Company Limited (A&C)
4	Moore AISC Auditing and Informatics Services Company Limited (Moore AISC)
5	PwC (Vietnam) Limited (PwC)
6	Grant Thornton (Vietnam) Limited (GT)
7	AAC Auditing and Accounting Company Limited (AAC)
8	Southern Auditing & Accounting Financial Consulting Services Company Limited (AASCS)
9	PKF-TTG Auditing and Consulting Company Limited (PKF-TTG)
10	RSM Vietnam Auditing & Consulting Company Limited (RSM)
11	Vietnam Auditing and Valuation Company Limited (VAE)
12	BDO Audit Company Limited (BDO)
13	Deloitte Vietnam Audit Company Limited (Deloitte)
14	Vietvalues Audit and Consulting Company Limited (VIETVALUES)
15	International Auditing Company Limited (ICPA)
16	Ernst & Young Vietnam Limited (E&Y)
17	UHY Auditing and Consulting Company Limited (UHY)
18	Nhan Tam Viet Auditing Company Limited (NTV)
19	AFC Vietnam Auditing Company Limited (AFC)
20	VACO Auditing Company Limited (VACO)
21	ECOVIS AFA VIETNAM Auditing - Valuation and Consulting Company Limited (ECOVIS AFA)
22	ASCO Auditing and Valuation Firm Company Limited (ASCO)
23	NVA Auditing Company Limited (NVA)
24	An Viet Auditing Company Limited (An Viet)
25	International Auditing and Valuation Company Limited (IAV)
26	Vietnam Auditing and Valuation Company Limited (AVA)
27	CPA VIETNAM Auditing Company Limited (CPA VN)
28	FAC Auditing Company Limited (FAC)



AMERICAN VIETNAMESE
BIOTECH INC

-----oOo-----

No.: 09/2026/AMV/TTr-HĐQT

THE SOCIALIST REPUBLIC OF VIETNAM
Independence – Freedom – Happiness

-----oOo-----

Hanoi, June 08, 2026

PROPOSAL OF THE BOARD OF DIRECTORS

On the update of the Company's business line codes

To: The General Meeting of Shareholders of American Vietnamese Biotech Inc

- Pursuant to the Law on Enterprises No. 59/2020/QH14 approved by the National Assembly of the Socialist Republic of Vietnam on June 17, 2020, and its guiding legal documents for implementation;
- Pursuant to the Law on Securities No. 54/2019/QH14 approved by the National Assembly of the Socialist Republic of Vietnam on November 26, 2019, and its guiding legal documents for implementation;
- Pursuant to Decree No. 155/2020/NĐ-CP issued by the Government on December 31, 2020, detailing the implementation of a number of articles of the Law on Securities, and Decree No. 245/2025/NĐ-CP issued by the Government on September 11, 2025, amending and supplementing a number of articles of Decree No. 155/2020/NĐ-CP;
- Pursuant to Decision No. 36/2025/QĐ-TTg of the Prime Minister issued on September 29, 2025, on the Vietnam Standard Industrial Classification;
- Pursuant to the Charter of American Vietnamese Biotech Inc.

The Board of Directors ("BOD") of American Vietnamese Biotech Inc ("the Company" or "AMV") respectfully submits to the General Meeting of Shareholders ("GMS") regarding the update of the Company's business line codes as follows:

1. To update the Company's business line codes in accordance with Decision No. 36/2025/QĐ-TTg dated September 29, 2025, of the Prime Minister on the issuance of the Vietnam Standard Industrial Classification and in alignment with the Company's actual business operations (*Detailed details are provided in the Appendix attached with this Proposal*).
2. To update Clause 1, Article 4 – Business Sectors in the current Charter of the Company, in alignment with the contents in Article 1 mentioned above.
3. To assign and authorize the Director/Legal Representative of the Company to:
 - Decide, direct the execution, and sign dossiers and documents related to the update of the Company's business line codes at competent state authorities (including updating, amending, and supplementing detailed contents within the scope of the business line codes specified in the Appendix attached with this Proposal);

- Sign and issue the Company's Charter after being amended and supplemented in accordance with the contents approved by the GMS in this Proposal;
- Perform other necessary tasks to complete the procedures for changing business registration contents in compliance with legal regulations.

Respectfully submitted to the General Meeting of Shareholders for consideration and approval./.

Recipients:

- *As above;*
- *Archived: Admin.*

ON BEHALF OF THE BOARD OF DIRECTORS

CHAIRMAN OF THE BOD



NAKATANI YOSHITAKA

**APPENDIX: UPDATE OF BUSINESS LINE CODES OF
AMERICAN VIETNAMESE BIOTECH INC**

(Attached with Proposal No. 09/2026/AMV/TTr-HĐQT)

1. Removal of the Company's business lines with specific details as follows:

The removal of several business lines below is due to the fact that these codes are no longer regulated and/or have been replaced by the corresponding industry codes under the Vietnam Standard Industrial Classification issued under Decision No. 36/2025/QĐ-TTg dated September 29, 2025, by the Prime Minister.

No.	Business Lines to be Removed from the Registered Business Line List	Industry Code
1	Other Professional, Scientific and Technical Activities Not Elsewhere Classified Details: - Technology transfer services (excluding bill settlement, ratio information services and securities consultancy).	7490
2	Wholesale of Computers, Peripheral Equipment and Software	4651
3	Retail Sale of Computers, Peripheral Equipment, Software and Telecommunications Equipment in Specialized Stores	4741
4	Retail Sale of Electrical Household Appliances, Beds, Wardrobes, Tables, Chairs and Similar Furniture, Lighting Equipment and Other Household Articles Not Elsewhere Classified in Specialized Stores Details:- Retail sale of air conditioners.	4759
5	Retail Sale of Other New Goods in Specialized Stores Details: - Retail sale of generators (excluding retail sale of gas cylinders, liquefied petroleum gas (LPG), waste lubricating oil, gold bullion, hunting or sporting firearms and ammunition, and coins; excluding retail sale of chemicals at the head office; subject to Decision No. 64/2009/QĐ-UBND dated July 31, 2009 and Decision No. 79/2009/QĐ-UBND dated October 17, 2009 of the Ho Chi Minh City People's Committee).	4773
6	Wholesale of Motor Vehicles and Other Motor Vehicles	4511
7	Retail Sale of Passenger Cars (9 Seats or Fewer)	4512
8	Propagation and Cultivation of Annual Plant Seedlings	0131
9	Propagation and Cultivation of Perennial Plant Seedlings	0132

No.	Business Lines to be Removed from the Registered Business Line List	Industry Code
10	Manufacture of Beer and Malt Liquor	1103
11	Manufacture of Non-alcoholic Beverages and Mineral Water	1104
12	Manufacture of Electronic Components	2610
13	Manufacture of Computers and Peripheral Equipment	2620
14	Manufacture of Beds, Wardrobes, Tables and Chairs	3100
15	Electric Power Generation Details: - Excluding power transmission, national power dispatching, distribution grid management, multipurpose hydropower and nuclear power generation.	3511
16	Electric Power Transmission and Distribution Details: - Excluding power transmission and dispatching activities as prescribed in Decree No. 94/2017/ND-CP dated August 10, 2017 of the Government.	3512
17	Maintenance and Repair of Motor Vehicles and Other Motor Vehicles	4520
18	Sale of Motor Vehicle Parts and Accessories	4530
19	Retail Sale of Automotive Fuel in Specialized Stores Details: - Excluding LPG and waste lubricating oil trading.	4730
20	Short-term Accommodation Services Details: - Hotels; - Tourist villas; - Tourist apartments; - Tourist guesthouses; - Houses with rooms for tourists; - Not operated at the head office.	5510
21	Management Consultancy Activities Details: - Excluding financial, accounting and legal consultancy.	7020

No.	Business Lines to be Removed from the Registered Business Line List	Industry Code
22	Activities of Employment Placement Agencies and Labour Recruitment Services Details: - Activities of labour consultancy, placement and recruitment agencies.	7810
23	Temporary Employment Agency Activities Details: - Excluding labour outsourcing services.	7820
24	Human Resource Supply and Management Activities Details: - Domestic human resource supply and management services; - Excluding labour outsourcing services.	7830
25	Landscape Care and Maintenance Services	8130
26	Educational Support Services	8560
27	Sauna, Massage and Similar Health Enhancement Services (excluding Sports Activities) Details: - Not operated at the head office.	9610
28	Retail Sale of Pharmaceuticals, Medical Goods, Cosmetics and Toilet Articles in Specialized Stores Details: - Retail sale of pharmaceuticals; - Retail sale of medical equipment, medical instruments and testing chemicals (without chemical storage).	4772
29	Other Credit Granting Activities	6492
30	Manufacture of Cosmetics, Soap and Detergents, Cleaning and Polishing Preparations Details: - Excluding chemical manufacturing at the head office; - Without chemical storage.	2023

No.	Business Lines to be Removed from the Registered Business Line List	Industry Code
31	Retail Sale of Food in Specialized Stores Details: - Retail sale of functional foods.	4722
32	Other Specialized Wholesale Activities Not Elsewhere Classified Details: - Wholesale of fertilizers, pesticides and other agricultural chemicals; - Wholesale of other chemicals (excluding agricultural-use chemicals); - Wholesale of primary-form plastics; - Wholesale of rubber; - Wholesale of textile fibres, yarns and threads; - Wholesale of garment and footwear accessories; - Wholesale of metal and non-metal scrap and waste materials; - Other specialized wholesale activities not elsewhere classified.	4669

2. Addition of the Company's business lines with specific details as follows:

The addition of several business lines below (replacing the corresponding old business line codes that were removed in Section 1 above) aims to ensure compliance with the Vietnam Standard Industrial Classification issued under Decision No. 36/2025/QĐ-TTg dated September 29, 2025, by the Prime Minister. Concurrently, this maintains exactly the business lines that the Company is currently operating without generating any new business lines.

No.	Additional Business Lines	Industry Code
1	Other Remaining Professional, Scientific and Technical Activities Not Elsewhere Classified	7499
2	Wholesale of Motor Vehicles and Other Motor Vehicles	4661
3	Real Estate Brokerage Services	6821
4	Collection of Non-Timber Forest Products	0230
5	Retail Sale of Motor Vehicles and Other Motor Vehicles	4781

No.	Additional Business Lines	Industry Code
6	Retail Sale of Pharmaceuticals, Medical Goods, Cosmetics and Toilet Articles Details: - Retail sale of pharmaceuticals; - Retail sale of medical equipment, medical instruments and testing chemicals (without chemical storage).	4772
7	Manufacture of Cosmetics, Perfumes, Soap and Detergents, Cleaning and Polishing Preparations Details: - Excluding chemical manufacturing at the head office; - Without chemical storage.	2023
8	Wholesale of Computers, Peripheral Equipment and Software	4651
9	Retail Sale of Electrical Household Appliances, Beds, Wardrobes, Tables, Chairs and Similar Furniture, Lighting Equipment and Other Household Articles Not Elsewhere Classified	4759
10	Retail Sale of Information and Communication Technology Equipment Details: - Retail sale of computers; - Retail sale of software designed for general customers (excluding software customized to specific customer requirements).	4740
11	Manufacture of Beer	1103
12	Manufacture of Non-alcoholic Beverages and Mineral Water	1105
13	Business Management Consultancy and Other Management Consultancy Activities	7020
14	Temporary Employment Agency Activities	7821
15	Other Human Resource Supply Activities	7822
16	Landscape Service Activities	8130
17	Hotels and Similar Accommodation Services	5510

No.	Additional Business Lines	Industry Code
18	Other Short-term Accommodation Activities	5520
19	Other Tourism-related Activities	7990
20	Other Computer Programming Activities	6219
21	Retail Sale of Food in Specialized Stores Details: - Retail sale of functional foods.	4722



AMERICAN VIETNAMESE
BIOTECH INC

-----oOo-----

No.: 01/2026/AMV/NQ-DHĐCĐ

THE SOCIALIST REPUBLIC OF VIETNAM
Independence – Freedom – Happiness

-----oOo-----

Hanoi, June , 2026

DRAFT



RESOLUTION

THE 2026 ANNUAL GENERAL MEETING OF SHAREHOLDERS AMERICAN VIETNAMESE BIOTECH INC MỸ

- Pursuant to the Law on Enterprises No. 59/2020/QH14 approved by the National Assembly of the Socialist Republic of Vietnam on June 17, 2020, and its guiding legal documents for implementation;
- Pursuant to the Law on Securities No. 54/2019/QH14 approved by the National Assembly of the Socialist Republic of Vietnam on November 26, 2019, and its guiding legal documents for implementation;
- Pursuant to the Charter of American Vietnamese Biotech Inc;
- Pursuant to the Regulations on the Organization of the 2026 Annual General Meeting of Shareholders approved by the General Meeting of Shareholders of American Vietnamese Biotech Inc (hereinafter referred to as the "Company" or "AMV") on June, 2026;
- Pursuant to the Minutes of Voting Ballot Counting at the 2026 Annual General Meeting of Shareholders of American Vietnamese Biotech Inc dated June, 2026;
- Pursuant to the Minutes of the 2026 Annual General Meeting of Shareholders of American Vietnamese Biotech Inc dated June, 2026.

RESOLVED

Article 1: To approve the Report on the BOD's performance in 2025 and operational orientations for 2026 (Attached with Report No. 01/2026/AMV/BC-HĐQT).

Article 2: To approve the Report on the performance of the Independent Members of the BOD and the evaluation results of the BOD's operations in 2025 (Attached with Report No. 02/2026/AMV/BC-HĐQT).

Article 3: To approve the Report on the 2025 business performance by the Board of Management and the 2026 business plan (Attached with Report No. 03/2026/AMV/BC-BGD).

Article 4: To approve the Report on the BOS's operations in 2025 and operational plan for 2026 (Attached with Report No. 04/2026/AMV/BC-BKS).

Article 5: To approve the Proposal of the BOD on the approval of the Audited 2025 Financial Statements (Attached with Proposal No. 05/2026/AMV/TTr-HĐQT).

Article 6: To approve the Proposal of the BOD on the approval of the 2025 profit distribution plan (Attached with Proposal No. 06/2026/AMV/TTr-HĐQT).

Article 7: To approve the Proposal of the BOD on the remuneration plan for the BOD and the



BOS in 2025 and the remuneration budget for 2026 *(Attached with Proposal No. 07/2026/AMV/TTr-HĐQT)*.

Article 8: To approve the Proposal of the BOS on the selection of an auditing firm for the 2026 Financial Statements *(Attached with Proposal No. 08/2026/AMV/TTr-BKS)*.

Article 9: To approve the update of the Company's business lines and sectors *(Attached with Proposal No. 09/2026/AMV/TTr-HĐQT)*.

Article 10: Implementation provisions

This Resolution was approved in its entirety by the 2026 Annual General Meeting of Shareholders of American Vietnamese Biotech Inc at the Meeting and shall take effect from June, 2026.

Members of the Board of Directors, the Board of Supervisors, and the Board of Management of the Company, based on their respective functions, duties, and authorities, shall be responsible for organizing and implementing the contents of this Resolution.

Recipients:

- General Meeting of Shareholders (GMS);
- BOD, BOS;
- Board of Management;
- Archived: Admin.

**ON BEHALF OF THE GENERAL MEETING OF
SHAREHOLDERS
CHAIRMAN OF THE MEETING**

